Investigational drug · Phase 3
SHR6390
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 1, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
53
Any phase or sponsor naming "SHR6390"
First trial start
2021
Apr 30, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR6390", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR6390" as an intervention, largest first.
- Phase III Study :SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 NegativePivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04842617 · 5,274 participants · Start Apr 30, 2021 · Primary completion Oct 31, 2026
Drug: SHR6390; placebo · For: Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast Cancer
Sites: Shanghai, China
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- SNF Platform Study of HR+/ HER2-advanced Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05594095 · 620 participants (planned) · Start Dec 30, 2022 · Primary completion Dec 1, 2025
Drug: PIK3CA inhibitor; AKT inhibitor and 17 more · For: Breast Neoplasm; Breast Cancer; Hormone Receptor Positive Tumor and 2 more
Sites: Shanghai, China
- A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03966898 · 426 participants (planned) · Start Jul 19, 2019 · Primary completion Dec 30, 2022
Drug: SHR6390 Tablets; Placebo Tablets and 1 more · For: Advanced Breast Cancer
Sites: Shanghai, China
Hebei Medical University Fourth HospitalAcademic, hospital or other
NCT05578053 · 420 participants (planned) · Start Sep 13, 2024 · Primary completion Dec 1, 2028
Drug: Dalpiciclib · For: Breast Cancer
Sites: Shijiazhuang, China
- ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerPivotal-lookingRecruiting
Peking University People's HospitalAcademic, hospital or other
NCT06970912 · 393 participants (planned) · Start Aug 1, 2025 · Primary completion Dec 31, 2029
Drug: Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy; Taxane-Based Neoadjuvant Chemotherapy · For: Hormone Receptor-Positive Breast Cancer; High-risk Breast Cancer; Early-Stage Breast Cancer and 3 more
Sites: Beijing, China
- A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03927456 · 357 participants (planned) · Start Jun 13, 2019 · Primary completion Dec 30, 2021
Drug: SHR6390; Placebo and 1 more · For: Advanced Breast Cancer
Sites: Beijing, China
- Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02Pivotal-lookingStatus unknown
Fudan UniversityAcademic, hospital or other
NCT05205200 · 338 participants (planned) · Start Jun 6, 2022 · Primary completion Feb 1, 2025
Drug: SHR-1316; SHR6390 and 3 more · For: Breast Cancer; Metastatic Cancer
Sites: Shanghai, China
Fudan UniversityAcademic, hospital or other
NCT04355858 · 319 participants (planned) · Start May 1, 2020 · Primary completion May 1, 2023
Drug: SHR7390; Famitinib and 13 more · For: Breast Cancer; Metastatic Cancer
Sites: Shanghai, China
- Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05949541 · 265 participants (planned) · Start Jul 26, 2023 · Primary completion Jul 2026
Drug: Everolimus 10 mg; CDK4/6 Inhibitor SHR6390 and 1 more · For: Breast Cancer; Advanced Breast Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- The synergistic tumor suppressor effect of CDK4/6 inhibitors and BRD4 inhibitors in acute myeloid leukemia.
Liao K, Guo C, Zhang M, et al. · Leuk Res Rep 2026
- Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review.
Chen Z, Xie P, Chen Q, et al. · Breast Cancer (Dove Med Press) 2025
- Effect of Efavirenz on the Pharmacokinetics of SHR6390 in Healthy Volunteers.
Wang J, Hu C, Zhang L · Drug Des Devel Ther 2024
- The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification.
Shi C, Ju H, Zhou R, et al. · BMC Med 2024
- SHR6390 Combined with Cabozantinib Inhibits Tumor Progression in the Hepatocellular Carcinoma Mouse Model.
Liu C, Shi J, Lin B, et al. · Curr Gene Ther 2024
- A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans.
Zhang H, Yan S, Zhan Y, et al. · Front Pharmacol 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.